Home » District Court Rejects ViroPharma Motion to Block Vancocin Generics
District Court Rejects ViroPharma Motion to Block Vancocin Generics
The U.S. District Court for the District of Columbia has denied ViroPharma’s motion for a temporary injunction to require the FDA to withdraw its approval of three generics of the gastrointestinal antibiotic Vancocin. The company filed a complaint and restraining order in the district court after the FDA rejected its 2006 citizen petition protesting changes to bioequivalence standards for Vancocin (vancomycin HCl) generics.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May